Use of cannabidiol in the treatment of epilepsy: Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex

Imagem de Miniatura
Arquivos
art_SILVINATO_Use_of_cannabidiol_in_the_treatment_of_epilepsy_2022.PDF (943.22 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ASSOC MEDICA BRASILEIRA
Autores
SILVINATO, Antonio
FLORIANO, Idevaldo
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.68, n.10, p.1345-1357, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: The objective of this systematic review with meta-analysis was to evaluate the efficacy, safety, and short-and long-term tolerability of cannabidiol (CBD), as an adjunct treatment, in children and adults with Dravet syndrome (SD), Lennox-Gataut syndrome (LGS), or tuberous sclerosis complex (TSC), with inadequate control of seizures.METHODS: This systematic review was conducted through a search for scientific evidence in the Mediline/PubMed, Central Cochrane, and ClinicalTrials. gov databases until April 2022. Selected randomized clinical trials (RCTs) that presented the outcomes: reduction in the frequency of seizures and total seizures (all types), number of patients with a response greater than or equal to 50%, change in caregiver global impression of change (CGIC) (improvement >= 1 category on the initial scale), adverse events (AEs), and tolerability to treatment. This review followed Preferred Reporting Items for Systematic reviews and Meta-Analyses.RESULTS: Notably, six RCTs were included, with a total of 1,034 patients with SD, LGS, and TSC, of which 3 were open-label extension RCTs. The meta-analysis of the studies showed that the use of CBD as compared with placebo, in patients with convulsive seizures refractory to the use of medications, reduces the frequency of seizures by 33%; increases the number of patients with a reduction >= 50% in the frequency of seizures by 20%; increases the number of patients with absence of seizures by 3%; improves the clinical impression evaluated by the caregiver or patient (S/CGIC) in 21%; increases total AEs by 12%; increases serious AE by 16%; increases the risk of treatment abandonment by 12%; and increases the number of patients with transaminase elevation (>= 3 times the referral) by 15%.CONCLUSIONS: This systematic review, with meta-analysis, supports the use of CBD in the treatment of patients with seizures, originated in DS, LGS, and TSC, who are resistant to the common medications, presenting satisfactory benefits in reducing seizures and tolerable toxicity.
Palavras-chave
Dravet syndrome, Lennox Gastaut syndrome, Tuberous sclerosis complex, Cannabidiol, Seizures, Seizures refractory
URI
https://observatorio.fm.usp.br/handle/OPI/51829
Referências
  1. [Anonymous], 2020, REV MAN REVMAN COMP
  2. Bourgeois BFD, 2014, EPILEPSIA, V55, P4, DOI 10.1111/epi.12567
  3. Cilio MR, 2014, EPILEPSIA, V55, P787, DOI 10.1111/epi.12635
  4. Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254
  5. Devinsky O, 2018, NEW ENGL J MED, V378, P1888, DOI 10.1056/NEJMoa1714631
  6. Devinsky O, 2017, NEW ENGL J MED, V377, P699, DOI 10.1056/NEJMc1708349
  7. Devinsky O, 2014, EPILEPSIA, V55, P791, DOI 10.1111/epi.12631
  8. Dravet C, 2013, HAND CLINIC, V111, P627, DOI 10.1016/B978-0-444-52891-9.00065-8
  9. GRADE, WHAT IS GRADE
  10. GRADEpro GDT, GRADEPRO UKRAINE GRA
  11. Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]
  12. Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
  13. Miller I, 2020, JAMA NEUROL, V77, P613, DOI 10.1001/jamaneurol.2020.0073
  14. Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
  15. Montouris GD, 2014, EPILEPSIA, V55, P10, DOI 10.1111/epi.12732
  16. Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001
  17. Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1016/j.ijsu.2021.105906, 10.1136/bmj.n71]
  18. Patel AD, 2021, EPILEPSIA, V62, P2228, DOI 10.1111/epi.17000
  19. Resnick T, 2017, J CHILD NEUROL, V32, P947, DOI 10.1177/0883073817714394
  20. Scheffer IE, 2021, EPILEPSIA, V62, P2505, DOI 10.1111/epi.17036
  21. Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
  22. Thiele EA, 2022, EPILEPSIA, V63, P426, DOI 10.1111/epi.17150
  23. Thiele EA, 2021, JAMA NEUROL, V78, P285, DOI 10.1001/jamaneurol.2020.4607
  24. Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3
  25. Wallace A, 2016, PEDIATR DRUGS, V18, P197, DOI 10.1007/s40272-016-0171-7
  26. Wezyk K, 2020, NEUROL NEUROCHIR POL, V54, P434, DOI 10.5603/PJNNS.a2020.0059
  27. Wirrell Elaine, 2016, Continuum (Minneap Minn), V22, P60, DOI 10.1212/CON.0000000000000269

Coleções
Artigos e Materiais de Revistas Científicas - HC/Outros
Artigos e Materiais de Revistas Científicas - LIM/47